NCT04288713View on ClinicalTrials.gov

Eculizumab (Soliris) in Covid-19 Infected Patients

AVAILABLEEXPANDED_ACCESS
Timeline

Start Date

Not specified

Conditions
Coronavirus
Interventions
DRUG

Eculizumab

A distal complement inhibitor.

Sponsors

Lead Sponsor

Hudson Medical
All Listed Sponsors
lead

Hudson Medical

OTHER

NCT04288713 - Eculizumab (Soliris) in Covid-19 Infected Patients | Biotech Hunter | Biotech Hunter